Biotechnology Value Fund L P SC 13G Monte Rosa Therapeutics / BIOTECHNOLOGY VALUE FUND L P ownership change

Exhibit 99.1

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated January 31, 2025 with respect to the Common Stock, $0.0001 par value per share, of Monte Rosa Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

BIOTECHNOLOGY VALUE FUND L P
By:	/s/ Mark N. Lampert
	Mark N. Lampert, Authorized Signatory
Date:	01/31/2025

BVF I GP LLC
By:	/s/ Mark N. Lampert
	Mark N. Lampert, Authorized Signatory
Date:	01/31/2025

BIOTECHNOLOGY VALUE FUND II LP
By:	/s/ Mark N. Lampert
	Mark N. Lampert, Authorized Signatory
Date:	01/31/2025

BVF II GP LLC
By:	/s/ Mark N. Lampert
	Mark N. Lampert, Authorized Signatory
Date:	01/31/2025

Biotechnology Value Trading Fund OS LP
By:	/s/ Mark N. Lampert
	Mark N. Lampert, Authorized Signatory
Date:	01/31/2025

BVF Partners OS Ltd.
By:	/s/ Mark N. Lampert
	Mark N. Lampert, Authorized Signatory
Date:	01/31/2025

BVF GP HOLDINGS LLC
By:	/s/ Mark N. Lampert
	Mark N. Lampert, Authorized Signatory
Date:	01/31/2025

BVF PARTNERS L P/IL
By:	/s/ Mark N. Lampert
	Mark N. Lampert, Authorized Signatory
Date:	01/31/2025

BVF INC/IL
By:	/s/ Mark N. Lampert
	Mark N. Lampert, Authorized Signatory
Date:	01/31/2025

LAMPERT MARK N
By:	/s/ Mark N. Lampert
	Mark N. Lampert
Date:	01/31/2025